Instrument Inactif

Communiqués Novelion Therapeutics Inc Nasdaq

Actions

CA7469271026

Cours en clôture Nasdaq
- ^USD	-

Communiqués

08/07/14	QLT : INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Sale of Auxilium Pharmaceuticals Inc.: - AUXL	PR
01/07/14	QLT : Dividends, Mergers, and Study Results - Analyst Notes on Pfizer, Gilead, Pacira, QLT and Agenus	PR
30/06/14	QLT : INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of Auxilium Pharmaceuticals Inc. and Its Board of Directors In Connection With the Sale of the Company to QLT Inc. -- AUXL	PR
24/09/12	QLT Inc. : Valeant Pharmaceuticals Acquires Visudyne® From QLT	PR
31/05/11	QLT INC : QLT Announces Issuance of U.S. Patent for Use of QLT091001 in Treatment of Inherited or Age-Related Retinal Diseases	PU
22/12/09	QLT INC : QLT Inc. establishes sales force in the United States	PR
15/12/09	QLT INC : QLT initiates Phase Ib study of QLT091001 in Leber Congenital Amaurosis	PR
09/12/09	QLT INC : 6-month results from EVEREST study evaluating Visudyne(R) therapy in patients with polypoidal choroidal vasculopathy	PR
25/11/09	QLT INC : QLT announces MGH litigation settlement	PR
28/10/09	QLT INC : QLT announces Toronto Stock Exchange approval of share repurchase program	PR
27/10/09	QLT INC : QLT Announces Share Repurchase Program	PR
27/10/09	QLT INC : QLT announces third quarter results for 2009	PR
19/10/09	QLT INC : QLT restructures Visudyne(R) agreement	PR
01/10/09	QLT INC : QLT announces sale of QLT USA, Inc. for up to US$230 million	PR
08/09/09	QLT INC : QLT announces receipt of a CDN$45.3 million tax refund	PR
28/07/09	QLT INC : QLT Announces Second Quarter Results for 2009	PR
28/07/09	QLT INC : QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System	PR
30/11/-1	QLT : announces encouraging Phase II data from core study of Punctal Plug Drug Delivery System	PR
30/11/-1	QLT : announces third quarter 2008 Visudyne(R) sales	PR
30/11/-1	QLT : announces the initiation of a Phase I trial of its synthetic retinoid product	PR
30/11/-1	QLT : announces completion of the redemption of 3% Convertible Senior Notes due 2023	PR
30/11/-1	QLT : completes Cdn$65.5 million real estate transaction	PR
30/11/-1	QLT : announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.	PR
30/11/-1	QLT : announces redemption of 3% convertible senior notes due 2023	PR
30/11/-1	QLT : announces removal of conditions on Cdn$65.5 million real estate transaction	PR